Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Unleashing market forces

Back to School Innovation & leadership

Gilead Sciences Inc. expects Indian-made generic versions of two of its biggest selling drugs to hit the market over the next three to six months, not because of patent expirations or political shenanigans, but by design. The company, which has long been proactive in developing global pricing principles, has licensed IP and transferred the necessary technologies to 10 Indian manufacturers to produce and distribute the products in poor countries.

GILD believes this method of IP management is the best way to reach resource-limited countries that do not have access to life-saving drugs while protecting its business in

Read the full 974 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers